NCT00124007View on ClinicalTrials.gov

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

April 30, 2007

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC-HIVADV014-00-VP

BIOLOGICAL

VRC-HIVDNA016-00-VP

Trial Locations (3)

Unknown

KEMRI, Ctr. for Geographic Medicine Research Coast at Kilifi, Kilifi

KAVI, KNH at Kangemi, Nairobi

Projet San Francisco, Kigali

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00124007 - Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults | Biotech Hunter | Biotech Hunter